Uppthera Inc. has patented new NLRP3 inflammasome inhibitors potentially useful for the treatment of cancer, metabolic and autoimmune diseases, cardiovascular, inflammatory, neurological, renal and respiratory disorders, among others.
The aberrant activation of NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome is a known crucial driver of neuroinflammation in Alzheimer’s disease (AD) and other related dementias. The inhibition of NLRP3 has shown benefits in preclinical models. Researchers from the University of Texas recently presented data regarding an NLRP3 inhibitor, AMS-17, for the treatment of AD and related dementias.
Zhejiang Pantheon Innovation Pharmaceutical Co. Ltd. has disclosed prodrugs of an NLRP3 inflammasome inhibitor compound. They are reported to be useful for the treatment of cancer and inflammation.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, cardiometabolic syndrome, cardiovascular disorders, Parkinson’s disease and Alzheimer’s disease.
Kangbaida (Sichuan) Biotechnology Co. Ltd. has disclosed pyroptosis and NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, type 1 diabetes, gout, inflammatory disorders, multiple sclerosis, psoriasis, autoimmune diseases and Alzheimer’s disease.
Neushen Therapeutics Inc. has patented NLRP3 inflammasome inhibitors reported to be useful for the treatment of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis and Huntington’s disease.
NLRP3 inflammasome is a key component of the innate immune system. As a major mediator of inflammation, NLRP3 plays a central role in the pathogenesis of neurodegenerative and autoinflammatory conditions.
Beijing Primegene Therapeutics Co. Ltd. has discovered NLRP3 inflammasome inhibitors reported to be useful for the treatment of sepsis, stroke, atherosclerosis, gout, Alzheimer's disease, Parkinson’s disease, type I diabetes and cancer, among others.
AC Immune SA has synthesized new heterocyclic modulators acting as NLRP3 inflammasome inhibitors. As such, they are reported to be potentially useful for the treatment of asthma, atherosclerosis, obesity, gout, cryopyrin-associated periodic syndromes, nonalcoholic fatty liver disease (NAFLD), Parkinson’s and Alzheimer’s disease, among others.
